Literature DB >> 12557283

Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration.

Raju Kapoor1, Meirion Davies, Paul A Blaker, Susan M Hall, Kenneth J Smith.   

Abstract

Axonal degeneration can be an important cause of permanent disability in neurological disorders in which inflammation is prominent, including multiple sclerosis and Guillain-Barré syndrome. The mechanisms responsible for the degeneration remain unclear, but it is likely that axons succumb to factors produced at the site of inflammation, such as nitric oxide (NO). We previously have shown that axons exposed to NO in vivo can undergo degeneration, especially if the axons are electrically active during NO exposure. The axons may degenerate because NO can inhibit mitochondrial respiration, leading to intraaxonal accumulation of Na(+) and Ca(2+) ions. Here, we show that axons can be protected from NO-mediated damage using low concentrations of Na(+) channel blockers, or an inhibitor of Na(+)/Ca(2+) exchange. Our findings suggest a new strategy for axonal protection in an inflammatory environment, which may be effective in preventing the accumulation of permanent disability in patients with neuroinflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12557283     DOI: 10.1002/ana.10443

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  53 in total

Review 1.  Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

Authors:  Ludwig Kappos; Jens Kuhle; Achim Gass; Lutz Achtnichts; Ernst-Wilhelm Radue
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla.

Authors:  M Inglese; G Madelin; N Oesingmann; J S Babb; W Wu; B Stoeckel; J Herbert; G Johnson
Journal:  Brain       Date:  2010-01-27       Impact factor: 13.501

3.  N-type calcium channel in the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Naoki Tokuhara; Kana Namiki; Mai Uesugi; Chihiro Miyamoto; Makoto Ohgoh; Katsutoshi Ido; Takashi Yoshinaga; Toshihiko Yamauchi; Junro Kuromitsu; Sadao Kimura; Norimasa Miyamoto; Yoshitoshi Kasuya
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

Review 4.  Multiple sclerosis: new insights and trends.

Authors:  M Inglese
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

5.  Neuroprotective effect of etomidate in the central nervous system of streptozotocin-induced diabetic rats.

Authors:  Ozkan Ates; Neslihan Yucel; Suleyman R Cayli; Eyup Altinoz; Saim Yologlu; Ayhan Kocak; Celal Ozbek Cakir; Yusuf Turkoz
Journal:  Neurochem Res       Date:  2006-06-21       Impact factor: 3.996

6.  Mitochondrial immobilization mediated by syntaphilin facilitates survival of demyelinated axons.

Authors:  Nobuhiko Ohno; Hao Chiang; Don J Mahad; Grahame J Kidd; LiPing Liu; Richard M Ransohoff; Zu-Hang Sheng; Hitoshi Komuro; Bruce D Trapp
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

7.  Plasma membrane calcium ATPase deficiency causes neuronal pathology in the spinal cord: a potential mechanism for neurodegeneration in multiple sclerosis and spinal cord injury.

Authors:  Michael P Kurnellas; Arnaud Nicot; Gary E Shull; Stella Elkabes
Journal:  FASEB J       Date:  2004-12-02       Impact factor: 5.191

8.  Axonal degeneration as a self-destructive defense mechanism against neurotropic virus infection.

Authors:  Ikuo Tsunoda
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

Review 9.  Roles of channels and receptors in the growth cone during PNS axonal regeneration.

Authors:  Sangwoo Shim; Guo-li Ming
Journal:  Exp Neurol       Date:  2009-10-13       Impact factor: 5.330

Review 10.  Mechanisms of neuronal damage in multiple sclerosis and its animal models: role of calcium pumps and exchangers.

Authors:  M P Kurnellas; K C Donahue; S Elkabes
Journal:  Biochem Soc Trans       Date:  2007-11       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.